872703-56-5

Upstream product

• 1313358-58-5 (S,E)-methyl 1-(2-benzylidenehydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 198904-78-8 methyl (S)-(1-hydrazinyl-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
• 198904-77-7 (S)-N'-(2-methoxycarbonylamino-3,3-dimethyl-butyryl)-hydrazinecarboxylic acid tert-butyl ester 
• 162537-11-3 (S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoic acid 
• 20859-02-3 L-tert-Leucine 
• 20570-96-1 benzylhydrazine dihydrochloride 
• 100-52-7 benzaldehyde 

Downstream Products

• 857904-19-9 methyl (S)-1-(2-benzyl-2-((2S,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 857900-57-3 methyl (S)-1-(2-((2S,3S)-3-amino-2-hydroxy-4-phenylbutyl)-2-benzylhydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-32-5 methyl (S)-1-(2-benzyl-2-((2S,3S)-2-hydroxy-3-((1S,3R)-3-(methoxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-4-phenylbutyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-33-6 methyl (S)-1-(2-((2S,3S)-3-((1S,3R)-3-acetamido-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)-2-benzylhydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 
• 1313358-34-7 methyl (S)-1-(2-benzyl-2-((2S,3S)-3-((1S,3R)-3-(tert-butoxycarbonylamino)-2,2-dimethylcyclobutanecarboxamido)-2-hydroxy-4-phenylbutyl)hydrazinyl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate 

Relevant academic research and scientific papers

NOVEL AZA-PEPTIDES CONTAINING 2,2-DISUBSTITUTED CYCLOBUTYL AND/OR SUBSTITUTED ALKOXY BENZYL DERIVATIVES AS ANTIVIRALS

The present invention relates to novel aza-peptides containing 2,2-disubstituted 5 cyclobutyl and/or substituted alkoxy benzyl derivatives of formula (I) and compositions for inhibiting Human Immunodeficiency Virus (HIV) and process for making the compounds.

Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol- containing transition-state mimic

A new generation of HIV-1 protease inhibitors encompassing a tertiary-alcohol-based transition-state mimic has been developed. By elongation of the core structure of recently reported inhibitors with two carbon atoms and by varying the P1′ group of the co

HIV protease inhibitors

Compounds of the formula (I): Wherein R1, R2, X and N are as defined in the specification; E is N, CH; A1 and A" are terminal groups as defined in the specification. The compounds have utility as HIV-I protease inhibitors.

A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold

Novel HIV-1 protease inhibitors encompassing a tertiary alcohol as part of the transition-state mimicking unit have been synthesized. Variation of the P1′-P3′ residues and alteration of the tertiary alcohol absolute stereochemistry a